Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07704892 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

Name: A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) — clinical trial record (NCT07704892)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: NEBULA-2

StatusRecruiting

PhasePhase 3

SponsorGlaxoSmithKline

Started2026-07-22

View on ClinicalTrials.gov ↗

This is a multi-center, randomized, two-part (Part A and Part B) study investigating the safety and efficacy of efimosfermin alfa in adult participants with compensated cirrhosis due to MASH. Participants who complete the treatment during Part A of the study and meet the inclusion criteria will have the option to enroll in Part B (open label) of the study.

Amendment history 1 change detected by DataLookout

2026-08-06

Recruitment opened

Trial Details

NCT Number	NCT07704892
Lead Sponsor	GlaxoSmithKline
Conditions	Metabolic Dysfunction-associated Steatohepatitis
Enrollment	380 participants
Start Date	2026-07-22
Primary Completion	2030-10-16 (estimated)
Study Completion	2033-12-08 (estimated)
Updated on ClinicalTrials.gov	2026-08-05